With sales declining for hepatitis C fixed-dose combo Viekira Pak, AbbVie Inc. wants to convince investors that its cancer portfolio and pipeline – led by hematology drugs Imbruvica and Venclexta – offer a pathway to sales growth that will enable the pharma to keep diversifying from top-seller Humira.
AbbVie has been criticized as a one-product shop since it was spun out of parent Abbott in 2013, and much...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?